SINGLETON J MATTHEW 4
4 · Viking Therapeutics, Inc. · Filed Sep 20, 2024
Insider Transaction Report
Form 4
SINGLETON J MATTHEW
Director
Transactions
- Sale
Common Stock, par value $0.00001 per share
2024-09-20$69.50/sh−10,300$715,850→ 9,500 total - Exercise/Conversion
Common Stock, par value $0.00001 per share
2024-09-20$1.19/sh+10,300$12,257→ 19,800 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-20−10,300→ 0 totalExercise: $1.19From: 2018-01-03Exp: 2027-01-03→ Common Stock (10,300 underlying)
Footnotes (1)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person.